| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Sulconazole nitrate targets fungal sterol synthesis. As an imidazole antifungal, it inhibits the enzyme lanosterol 14α-demethylase, a cytochrome P450 enzyme involved in the synthesis of ergosterol, a key component of fungal cell membranes. By inhibiting sterol synthesis, it disrupts fungal cell membrane integrity, leading to fungal cell death. It has broad-spectrum antifungal activity against various fungi including Candida albicans.
|
|---|---|
| ln Vitro |
In vitro, Sulconazole nitrate exhibits broad-spectrum antifungal activity. It has a fungicidal effect and is also effective against the stationary phase of Candida albicans. It prevents fungal growth by inhibiting sterol synthesis. Quantitative MIC values for its antifungal activity against specific fungal strains are not detailed in the publicly available sources.
|
| ln Vivo |
In vivo, Sulconazole nitrate is used for the treatment of superficial and deep fungal infections, including skin and nail ringworm, vaginal candidiasis, gastrointestinal fungal infections, and systemic infections caused by various fungi. It is a broad-spectrum antifungal agent primarily used for the treatment of fungal skin infections. It is available in topical formulations.
|
| Enzyme Assay |
For in vitro cell-free assays, the antifungal activity of Sulconazole nitrate can be assessed using standard antifungal susceptibility testing. The compound is tested against various fungal strains (e.g., Candida albicans) using broth microdilution methods to determine the minimum inhibitory concentration (MIC). Its inhibition of sterol synthesis can be studied by measuring ergosterol levels in fungal cell extracts.
|
| Cell Assay |
For in vitro cellular assays, the antifungal activity of Sulconazole nitrate is assessed in fungal cultures using broth microdilution or agar dilution methods to determine MIC values. Its effects on fungal cell membrane integrity can be assessed by measuring cell viability and membrane permeability.
|
| Animal Protocol |
For in vivo studies, Sulconazole nitrate is typically applied topically in animal models of fungal skin infection or in clinical use. Endpoints include reduction in fungal load, improvement in skin lesions, and eradication of infection.
|
| ADME/Pharmacokinetics |
Sulconazole nitrate (CAS 82382-23-8) has a molecular formula of C18H15Cl3N2S·HNO3 and a molecular weight of 460.76 g/mol. It is also known as Sulconazole mononitrate. Appearance: typically a powder. Solubility: DMSO and other organic solvents. Storage: typical for antifungal agents (desiccated, protected from light, room temperature). Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
Sulconazole nitrate has a well-established clinical safety profile. Common side effects include local skin irritation, burning, and itching. It is generally well-tolerated when used topically. Systemic toxicity is minimal with topical use.
|
| References |
Tanenbaum L, Taplin D, Lavelle C, Akers WA, Rosenberg MJ, Carmargo G. Sulconazole nitrate cream 1 percent for treating tinea cruris and corporis. Cutis. 1989 Oct;44(4):344-7.
|
| Additional Infomation |
Suconazole nitrate is an organic nitrate belonging to the conazole and imidazole classes of antifungal drugs. Suconazole nitrate is the nitrate form of suconazole, a synthetic imidazole derivative with antifungal activity. Suconazole nitrate inhibits the C-14α-demethylation of fungal cytochrome P-450 sterols, leading to the accumulation of 14α-methylsterol in fungi, and inhibits the synthesis of ergosterol (an important component of the fungal cell membrane). Inhibition of ergosterol synthesis leads to disruption of cell membrane permeability, ultimately inhibiting cell wall synthesis. Furthermore, suconazole nitrate appears to interfere with the autolytic degradation of fungal DNA and RNA. See also: suconazole (containing the active moiety).
Sulconazole nitrate is an approved antifungal medication in many countries for the treatment of fungal skin infections. Its mechanism of action involves inhibition of fungal sterol synthesis, disrupting cell membrane integrity. It is available in topical formulations such as creams and solutions. It is not approved for systemic use in the United States. |
| Molecular Formula |
C18H15N2SCL3.HNO3
|
|---|---|
| Molecular Weight |
460.76194
|
| Exact Mass |
458.997
|
| CAS # |
82382-23-8
|
| Related CAS # |
61318-91-0 (nitrate) 61318-90-9 |
| PubChem CID |
65495
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
558.2ºC at 760 mmHg
|
| Flash Point |
291.4ºC
|
| LogP |
6.693
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
404
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=CC=C(C(SCC2=CC=C(Cl)C=C2)CN3C=CN=C3)C(Cl)=C1.[O-][N+](O)=O
|
| InChi Key |
CRKGMGQUHDNAPB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H15Cl3N2S.HNO3/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21;2-1(3)4/h1-9,12,18H,10-11H2;(H,2,3,4)
|
| Chemical Name |
1-[2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1703 mL | 10.8516 mL | 21.7033 mL | |
| 5 mM | 0.4341 mL | 2.1703 mL | 4.3407 mL | |
| 10 mM | 0.2170 mL | 1.0852 mL | 2.1703 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
